Unknown

Dataset Information

0

Nanomaterials-Mediated Co-Stimulation of Toll-Like Receptors and CD40 for Antitumor Immunity.

ABSTRACT: Toll-like receptors (TLRs) and CD40-related signaling pathways represent critical bridges between innate and adaptive immune responses. Here, an immunotherapy regimen that enables co-stimulation of TLR7/8- and CD40-mediated pathways is developed. TLR7/8 agonist resiquimod (R848) derived amino lipids, RAL1 and RAL2, are synthesized and formulated into RAL-derived lipid nanoparticles (RAL-LNPs). The RAL2-LNPs show efficient CD40 mRNA delivery to DCs both in vitro (90.8 ± 2.7%) and in vivo (61.3 ± 16.4%). When combined with agonistic anti-CD40 antibody, this approach can produce effective antitumor activities in mouse melanoma tumor models, thereby suppressing tumor growth, prolonging mouse survival, and establishing antitumor memory immunity. Overall, RAL2-LNPs provide a novel platform toward cancer immunotherapy by integrating innate and adaptive immunity.

SUBMITTER: Yan J 

PROVIDER: S-EPMC9691606 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Nanomaterials-Mediated Co-Stimulation of Toll-Like Receptors and CD40 for Antitumor Immunity.

Yan Jingyue J   Zhang Yuebao Y   Du Shi S   Hou Xucheng X   Li Wenqing W   Zeng Chunxi C   Zhang Chengxiang C   Cheng Jeffrey J   Deng Binbin B   McComb David W DW   Zhao Weiyu W   Xue Yonger Y   Kang Diana D DD   Cheng Xiaolin X   Dong Yizhou Y  

Advanced materials (Deerfield Beach, Fla.) 20221017 47

Toll-like receptors (TLRs) and CD40-related signaling pathways represent critical bridges between innate and adaptive immune responses. Here, an immunotherapy regimen that enables co-stimulation of TLR7/8- and CD40-mediated pathways is developed. TLR7/8 agonist resiquimod (R848) derived amino lipids, RAL1 and RAL2, are synthesized and formulated into RAL-derived lipid nanoparticles (RAL-LNPs). The RAL2-LNPs show efficient CD40 mRNA delivery to DCs both in vitro (90.8 ± 2.7%) and in vivo (61.3 ±   ...[more]

Similar Datasets

Unknown Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors.
| S-EPMC8542346 | biostudies-literature
Unknown Neoagarohexaose-mediated activation of dendritic cells via Toll-like receptor 4 leads to stimulation of natural killer cells and enhancement of antitumor immunity.
| S-EPMC5458676 | biostudies-literature
Unknown CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
| S-EPMC4917417 | biostudies-literature
Unknown Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor immunity.
| S-EPMC10050348 | biostudies-literature
Unknown Osteoarthritis and Toll-Like Receptors: When Innate Immunity Meets Chondrocyte Apoptosis.
| S-EPMC7235883 | biostudies-literature
Unknown CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling.
| S-EPMC10945091 | biostudies-literature
Unknown BPTF Depletion Enhances T-cell-Mediated Antitumor Immunity.
| S-EPMC5093041 | biostudies-literature
Unknown Co-stimulation of CD28/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness.
| S-EPMC11268112 | biostudies-literature
Unknown Genetic Diversity of Toll-Like Receptors and Immunity to M. leprae Infection.
| S-EPMC3317006 | biostudies-literature
Unknown Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.
| S-EPMC7106078 | biostudies-literature